AK002 is a therapeutic antibody that targets Siglec-8, an inhibitory receptor selectively expressed on mast cells and eosinophils. AK002’s novel mechanism of action is highly specific to mast cells and eosinophils and has potential treat a wide spectrum of severe conditions. Allakos has demonstrated the activity of AK002 in preclinical studies including respiratory, dermatological, gastrointestinal, and allergic disease models. AK002 was well-tolerated and demonstrated pharmacodynamic activity in two Phase I clinical trials.
AK003 is an antibody targeting a receptor on effector cells for use in immuno-oncology applications. The program is currently pre-clinical.